Verastem posts updated corporate presentation; no specific financial or clinical data disclosed in filing

Verastem, Inc.

Corporate presentation dated March 4, 2026, furnished as Exhibit 99.1 to Form 8-K.
Presentation titled 'Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers'.
No revenue, trial results, or other material metrics provided in the 8-K or the exhibit excerpt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.